Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A
BioMarin Pharmaceutical, a global biotechnology company dedicated to transforming lives through genetic discovery, today announced […]
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Cantex Pharmaceuticals, a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other […]
Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel […]
First CureDuchenne Clinic Opens in Greater Dallas Area to Provide Specialized Care for Underserved Duchenne Muscular Dystrophy Patients
CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, […]
Sooma Medical Receives FDA Breakthrough Device Designation for Its Innovative At-Home Depression Treatment Device
Sooma Medical, a medical device company based in Finland, has been granted Breakthrough Device designation […]
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]
Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, and Foundation […]
Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology
Flamingo Therapeutics and Dynacure announced today that the companies have signed a definitive merger agreement to […]
Debiopharm Extends Their DNA Damage Repair Footprint With New Oncology Pipeline Entry
Debiopharm, an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer […]
Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers
Tachyon Therapeutics, a private, clinical-stage biotechnology company developing transformative cancer therapies against novel targets today […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more